Drug Trial Radar · NCT05548296
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
Aug 29, 2022
Primary completion
May 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Acrivon TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- GOG Foundation
- First posted
- Sep 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Conditions
- Endometrial Adenocarcinoma
Interventions
ACR-368Drug
ACR-368 is an experimental drug
GemcitabineDrug
Sensitization of tumor cells is provided through administration of ULDG
OncoSignatureDiagnostic test
Prospective prediction of drug sensitivity based on a pretreatment tumor biopsy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive.Time frame: Response will be assessed every 8 weeks from baseline through 2 years or death.
- Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative.Time frame: Response will be assessed every 8 weeks from baseline through 2 years or death.
- Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers).Time frame: Response will be assessed every 8 weeks from baseline through 2 years or death.
- Arm 4: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers).Time frame: Response will be assessed every 8 weeks from baseline through 2 years or death.
Locations
90 sites in 5 countries. Site status is shown where the registry gives one.
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama · Completed
Alaska Women's Cancer Center
Anchorage, Alaska · Completed
HonorHealth
Phoenix, Arizona · Recruiting
Arizona Oncology Associate, PC- HOPE
Tucson, Arizona · Active not recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
City of Hope National Medical Center
Duarte, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
USC/Norris Comprehensive Cancer Center
Los Angeles, California · Completed
Cedars Sinai Medical Center
Los Angeles, California · Recruiting
Hoag Cancer Center
Newport Beach, California · Recruiting
UC Irvine Health
Orange, California · Completed
Stanford Cancer Center
Palo Alto, California · Recruiting
University of California, Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
University of California Los Angeles (UCLA)
Santa Monica, California · Recruiting
University of Colorado
Aurora, Colorado · Recruiting
Yale Cancer Center
New Haven, Connecticut · Completed
Florida Gynecologic Oncology/Regional Cancer Center
Fort Myers, Florida · Completed
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Northeast Georgia Medical Center
Gainesville, Georgia · Completed
Northwestern Medicine
Chicago, Illinois · Recruiting
University of Illinois Cancer Center
Chicago, Illinois · Recruiting
University of Chicago Medicine
Chicago, Illinois · Recruiting
Carle Cancer Center
Urbana, Illinois · Recruiting
Ascension St. Vicent Hospital, Inc.
Indianapolis, Indiana · Recruiting
University of Iowa
Iowa City, Iowa · Recruiting
LSU Health Sciences
New Orleans, Louisiana · Recruiting
Trials365, LLC
Shreveport, Louisiana · Recruiting
American Oncology Partners of Maryland PA
Bethesda, Maryland · Completed
National Institutes of Health, Clinical Center
Bethesda, Maryland · Active not recruiting
Holy Cross Hospital
Silver Spring, Maryland · Completed
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Massachusetts Chan Medical School
Worcester, Massachusetts · Completed
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
HCA Midwest
Kansas City, Missouri · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Rutgers Cancer Institute of NJ
New Brunswick, New Jersey · Recruiting
Laura & Isaac Perlmutter Cancer Center
New York, New York · Recruiting
New York Presbyterian Hospital-Columbia University Medical Center
New York, New York · Completed
Memorial Sloan-Kettering Cancer Center
New York, New York · Recruiting
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.